journal article·2019-09-24

Biomimetic Magnetic Nanostructures: A Theranostic Platform Targeting Lipid Metabolism and Immune Response in Lymphoma

Abhalaxmi Singh, Vikas Nandwana, Jonathan S. Rink, Soo-Ryoon Ryoo, Tzu Hung Chen, Sean David Allen, Evan A. Scott, Leo I. Gordon, C. Shad Thaxton, Vinayak P. Dravid

ACS Nano· Volume 13· Issue 9
Publisher page

Abstract

B-cell lymphoma cells depend upon cholesterol to maintain pro-proliferation and pro-survival signaling via the B-cell receptor. Targeted cholesterol depletion of lymphoma cells is an attractive therapeutic strategy. We report here high-density lipoprotein mimicking magnetic nanostructures (HDL-MNSs) that can bind to the high-affinity HDL receptor, scavenger receptor type B1 (SR-B1), and interfere with cholesterol flux mechanisms in SR-B1 receptor positive lymphoma cells, causing cellular cholesterol depletion. In addition, the MNS core can be utilized for its ability to generate heat under an external radio frequency field. The thermal activation of MNS can lead to both innate and adaptive antitumor immune responses by inducing the expression of heat shock proteins that lead to activation of antigen presenting cells and finally lymphocyte trafficking. In the present study, we demonstrate SR-B1 receptor mediated binding and cellular uptake of HDL-MNS and prevention of phagolysosome formation by transmission electron microscopy, fluorescence microscopy, and ICP-MS analysis. The combinational therapeutics of cholesterol depletion and thermal activation significantly improves therapeutic efficacy in SR-B1 expressing lymphoma cells. HDL-MNS reduces the T2 relaxation time under magnetic resonance imaging (MRI) more effectively compared with a commercially available contrast agent, and the specificity of HDL-MNS toward the SR-B1 receptor leads to differential contrast between SR-B1 positive and negative cells suggesting its utility in diagnostic imaging. Overall, we have demonstrated that HDL-MNSs have cell specific targeting efficiency, can modulate cholesterol efflux, can induce thermal activation mediated antitumor immune response, and possess high contrast under MRI, making it a promising theranostic platform in lymphoma.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Lymphoma Diagnosis and Treatment · Ovarian cancer diagnosis and treatment · Glycosylation and Glycoproteins Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Materials Science & Engineering, Northwestern University, Evanston, Illinois 60208, United States

International Institute of Nanotechnology, Evanston, Illinois 60208, United States

Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, United States

Simpson-Querrey Institute for Bionanotechnology, Northwestern University, Chicago, Illinois 60611, United States

Interdisciplinary Biological Sciences Program, Northwestern University, Evanston, Illinois 60208, United States

Department of Biomedical Engineering, Northwestern University, Evanston, Illinois 60208, United States

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois 60611, United States

Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, United States

Funding

Air Force Research Laboratory · Nanyang Technological University · International Institute for Nanotechnology, Northwestern University

References (52)

Show source-provided references
1. SEER Program (National Cancer Institute (U. S.)) SEER Cancer Statistics Review 1975–2013; http://seer.cancer.gov/csr/1975_2013 (Accessed September 12, 2016).
2. 10.1016/S0140-6736(12)60605-910.1016/S0140-6736(12)60605-9 ↗
3. 10.1073/pnas.121365711010.1073/pnas.1213657110 ↗
4. 10.1038/oncsis.2015.4910.1038/oncsis.2015.49 ↗
5. 10.1097/SMJ.0b013e3181fcd4b910.1097/SMJ.0b013e3181fcd4b9 ↗
6. 10.1158/0008-5472.CAN-07-021210.1158/0008-5472.CAN-07-0212 ↗
7. 10.1021/acs.molpharmaceut.7b0071010.1021/acs.molpharmaceut.7b00710 ↗
8. 10.1021/acs.chemmater.6b0535710.1021/acs.chemmater.6b05357 ↗
9. 10.3389/fimmu.2013.0043810.3389/fimmu.2013.00438 ↗
10. 10.3389/fimmu.2016.0017110.3389/fimmu.2016.00171 ↗
11. 10.4049/jimmunol.182.3.144910.4049/jimmunol.182.3.1449 ↗
12. 10.1080/0265673021016614010.1080/02656730210166140 ↗
13. Skitzki J. J. · Curr. Opin. Investig. Drugs · 2009 · 10 · 550
14. 10.1016/j.ejca.2008.07.03810.1016/j.ejca.2008.07.038 ↗
15. 10.3892/or.3.6.104310.3892/or.3.6.1043 ↗
16. 10.1002/1097-0142(19940415)73:8<2048::AID-CNCR2820730806>3.0.CO;2-Q10.1002/1097-0142(19940415)73:8<2048::AID-CNCR2820730806>3.0.CO;2-Q ↗
17. 10.1200/JCO.2005.05.52010.1200/JCO.2005.05.520 ↗
18. 10.1016/S0360-3016(97)00731-110.1016/S0360-3016(97)00731-1 ↗
19. 10.1016/S0140-6736(00)02059-610.1016/S0140-6736(00)02059-6 ↗
20. 10.1016/j.rpor.2013.09.01110.1016/j.rpor.2013.09.011 ↗
21. 10.1016/j.addr.2011.03.00810.1016/j.addr.2011.03.008 ↗
22. 10.1021/acsami.6b0137710.1021/acsami.6b01377 ↗
23. 10.1002/adma.20070197510.1002/adma.200701975 ↗
24. 10.1021/ja808856z10.1021/ja808856z ↗
25. 10.1194/jlr.R800010-JLR20010.1194/jlr.R800010-JLR200 ↗
26. 10.1126/science.271.5248.51810.1126/science.271.5248.518 ↗
27. Fidge N. H. · J. Lipid Res. · 1999 · 40 · 18710.1016/S0022-2275(20)33357-5 ↗
28. 10.3389/fphar.2016.0046610.3389/fphar.2016.00466 ↗
29. 10.1007/978-3-319-16555-4_610.1007/978-3-319-16555-4_6 ↗
30. 10.1021/nl104194710.1021/nl1041947 ↗
31. 10.1021/ar200017e10.1021/ar200017e ↗
32. 10.1002/anie.20090311210.1002/anie.200903112 ↗
33. 10.1182/blood-2016-08-68507310.1182/blood-2016-08-685073 ↗
34. 10.3348/kjr.2017.18.1.5410.3348/kjr.2017.18.1.54 ↗
35. 10.1021/bc800520d10.1021/bc800520d ↗
36. 10.1021/nl801958b10.1021/nl801958b ↗
37. 10.1016/j.biomaterials.2010.08.07810.1016/j.biomaterials.2010.08.078 ↗
38. 10.18632/oncotarget.1449410.18632/oncotarget.14494 ↗
39. 10.1038/s41598-017-18100-810.1038/s41598-017-18100-8 ↗
40. 10.1016/j.biomaterials.2012.08.05710.1016/j.biomaterials.2012.08.057 ↗
41. 10.1593/neo.10137210.1593/neo.101372 ↗
42. 10.1142/S179398441000006710.1142/S1793984410000067 ↗
43. 10.1038/srep3807210.1038/srep38072 ↗
44. 10.1039/C5NR02718G10.1039/C5NR02718G ↗
45. 10.3109/02656736.2014.96864010.3109/02656736.2014.968640 ↗
46. 10.21037/tcr.2017.01.0810.21037/tcr.2017.01.08 ↗
47. 10.1007/s11912-019-0789-z10.1007/s11912-019-0789-z ↗
48. Austyn J. M. · Immunology · 1988 · 63 · 691
49. 10.1136/annrheumdis-2013-20375610.1136/annrheumdis-2013-203756 ↗
50. 10.1038/ncomms406510.1038/ncomms4065 ↗
51. 10.1007/s12026-009-8115-810.1007/s12026-009-8115-8 ↗
52. 10.3389/fphar.2018.0083110.3389/fphar.2018.00831 ↗